Get the Stockscreener App
14.37
0.21%
0.04
After Hours:
14.37
Amicus Therapeutics Inc stock is traded at $14.37, with a volume of 2.83M.
It is up +0.21% in the last 24 hours and up +0.49% over the past month.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$14.33
Open:
$14.33
24h Volume:
2.83M
Relative Volume:
0.27
Market Cap:
$4.51B
Revenue:
$571.16M
Net Income/Loss:
$-38.10M
P/E Ratio:
-117.31
EPS:
-0.1225
Net Cash Flow:
$-48.91M
1W Performance:
+0.14%
1M Performance:
+0.49%
6M Performance:
+87.96%
1Y Performance:
+56.26%
1-Day Range:
$14.32
$14.37
1-Week Range:
$14.32
$14.37
52-Week Range:
$5.51
$14.38
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.37 | 4.50B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.76 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-29-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Growth in Rare Diseases with Strong Revenue Momentum - DirectorsTalk Interviews
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus - Yahoo Finance
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - The AI Journal
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
Amicus Therapeutics: Q4 Earnings Snapshot - kare11.com
Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses - Intellectia AI
Amicus Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives - Sahm
Will Amicus Therapeutics Inc. benefit from sector rotationEarnings Overview Report & Daily Entry Point Alerts - mfd.ru
Decoding Amicus Therapeutics Inc (FOLD): A Strategic SWOT Insigh - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results - MarketBeat
Amicus Therapeutics (FOLD) Beats Q4 Revenue Expectations - GuruFocus
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - The Manila Times
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
Is Amicus Therapeutics Inc.’s ROIC above industry averageWeekly Trading Summary & Intraday High Probability Setup Alerts - mfd.ru
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections - Finviz
Amicus earnings on deck as $4.8B BioMarin deal awaits vote - Investing.com India
Aug Levels: Will Amicus Therapeutics Inc benefit from geopolitical trendsWeekly Trend Report & Smart Investment Allocation Tips - baoquankhu1.vn
Principal Financial Group Inc. Has $2.08 Million Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Current Valuations with Strong Revenue Growth - DirectorsTalk Interviews
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
What to Expect From These Drug/Biotech Players This Earnings Season? - TradingView
BioMarin Debt Deal And VOXZOGO Approval Recast Rare Disease Outlook - Yahoo Finance
Can Amicus Therapeutics Inc. expand its profit marginsPortfolio Gains Summary & Smart Swing Trading Techniques - mfd.ru
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
Why Amicus Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Final Week & Trade Opportunity Analysis - mfd.ru
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Amicus Therapeutics (FOLD) to Release Earnings on Wednesday - MarketBeat
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
BioMarin to acquire Amicus for $14.50 per share in cash, or $4.8B - MSN
Amicus Therapeutics (FOLD) Stock Analysis: Navigating Growth In Rare Disease Biotech - DirectorsTalk Interviews
Metabolism Drugs Market Booming with Rapid Growth Through 2033 | - openPR.com
New York State Common Retirement Fund Raises Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments - Yahoo Finance
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Amicus to present new data on rare disease treatments at symposium - Investing.com Canada
Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a Focus on Growth and Revenue Potential - DirectorsTalk Interviews
Amicus (FOLD) Shares New Data at WORLDSymposium 2026 - GuruFocus
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - The Manila Times
Amicus Therapeutics Presents New Long-term Data for both - GlobeNewswire
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
BioMarin-Amicus file US antitrust paperwork, make EU referral request - MLex
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):